This report on global small animal respiratory diseases treatment market studies various type of diseases, drug class and geography. According to veterinary medical experts, upper respiratory infections– also called canine infectious respiratory disease (CIRD) is mainly caused in spaces occupied or visited by many pets such as boarding houses, groomers, and parks. These kind of infections are also known commonly as "Kennel Cough" because of the honking, dry sound made by infected animals, URI in pets is complex to diagnose because it can be caused by both bacteria or viruses and in most cases multiple agents are involved. These infections are highly contagious especially when dogs or cats get together in high-density situations such as pet stores and animal shelters the sanitization is the most important factor. 

For the purpose of this study, the various types of diseases considered are allergic pneumonitis, canine influenza, canine nasal mites, lung nematodes, neoplasia of respiratory system, pneumonia, rhinitis and sinusitis, tonsilitis, and others. 

The market segmentation on the basis types of drug class comprises sub-segments such as anthelmintics, NSAIDs, corticosteroids, antibiotics, antihistamines, phosphodiesterase (PDE) inhibitors, bronchodilators, antineoplastic agents, and others. 

The geographic segmentation of the global small animal respiratory diseases treatment market is performed for the regions North America, Europe, Asia-Pacific, Latin America and Middle East & Africa markets. The regions are also further sub-segmented on the basis of major countries. 

The key players covered in small animal respiratory diseases treatment market are Zoetis, Inc., Merck Animal Health, Merial Inc. (Sanofi S.A), Boehringer Ingelheim GmbH, Elanco Animal Health (Eli Lilly), Bayer AG, Ceva Animal Health, Heska Corporation, Vetoquinol SA, Virbac Ltd., and Cipla Vet.

In May 2013, Small Animal CPD Meeting sponsored by Boehringer Ingelheim Vetmedica involved discussion with experts about the common symptoms observed in small animals such as coughing or dyspnoea with common disorders such as brachycephalic  syndrome, laryngeal paralysis, tracheal collapse, and feline asthma syndrome.

According to market experts, allergic pneumonitis, canine influenza, rhinitis and sinusitis and tonsillitis were observed as the most common respiratory diseases observed in small animals. According to American Veterinary Medical Foundation, the first recognized U.S. outbreak of H3N2 canine influenza occurred in 2015, starting in Chicago and spreading to other Midwestern states. Since March 2015, outbreaks have occurred in a number of areas throughout the U.S. and thousands of dogs have been confirmed positive for the H3N2 virus. It was observed that prevalence of canine influenza was also observed in cats and the displayed signs of upper respiratory disease including discharge, congestion, malaise, lip smacking and excessive salivation. Rhinitis and sinusitis are considered as the most infrequent problems in small animals but with changes occurring in environment with presence of air pollution and sudden environmental change may lead to chronic nasal diseases. The breed predilections for rhinitis and sinusitis comprised short-nose flat-faced cats that are more prone to chronic inflammation of the nose and most of the times fungal rhinitis. In case of dogs it is mainly observed in dogs with a long head and nose and these dogs are more prone to Aspergillus infection and nasal tumors. According to a research paper published by Daniel L. Hamilos in ATS Journals, ambient mold spores are widely distributed in nature, and an estimated 3 to 10% of the world's animal population is allergic to molds. The research study also suggests that compelling epidemiologic links between mold (fungal) allergy and illnesses such as asthma and asthma with allergic rhinitis. Fungal allergy is more prevalent in areas of high ambient mold spore concentrations. Hence, market dynamics of small animals respiratory diseases treatment involved the developing pet keeping trend in urban population mostly involving small animals, rising air pollution and abrupt environmental changes are affecting respiratory health of small animals, and maintenance of unsanitary conditions around pets also affect their respiratory system. 

According to Royal Veterinary College, in U.K per 1000 dogs 23.2 dogs suffers with Kennel cough, 9.5 dogs suffer with coughing, 6.7 dogs are diagnosed with upper respiratory tract infection (URTI), and 3.9 dogs suffer with brachycephalic airway obstruction syndrome (BAOS).

In 2021, it was observed that anthelmintics, corticosteroids and antibiotics accounted for more than 50% market share of the overall small animal respiratory diseases treatment market. According to market experts, most anthelmintics have wide safety margins, i.e., the dosage that can be given to an animal before adverse effects are induced is much higher than the dosage recommended for use. Thus, anthelmintics are prescribed very cautiously in small animals as the dose plays very critical role in the treatment of the diseases and anticipated side-effects. The most commonly used antibiotics in small animal respiratory diseases treatment are amoxicillin and cephalexin, sulfamethox, gentamicin, chloramphenicol, sulfadimethoxine, tetracycline, and doxycycline. The bacteria’s growth and further multiplication is inhibited by bacteriostatic antibiotics. Glucocorticoids through several mechanisms project the anti-inflammatory and immunosuppressive actions in the body that helps to overcome respiratory diseases in small animals.

North America was observed as the largest market for small animal respiratory diseases treatment market due to factors such as rising air pollution, lack of sanitation related to pets in a few households, increasing urban trend of having dogs and cats as pets and rising awareness associated with the well-being of small animals. The European small animal respiratory diseases treatment market has displayed significant growth recently, albeit from a fairly low base compared to other regions. According to market experts, consumers in the region are more likely to own pets and provide them all the facilities as a family member. There is a noticeable inclination towards pet humanization, especially among young, urban and affluent consumers, and is expected to trade up to mid-priced or premium products. In 2015, Asia-Pacific was observed as the fastest growing small animal respiratory diseases treatment market due to key driving factors such as rising trend of keeping dogs and cats as pet in urban areas, increasing awareness in pet owners especially associated with several life-threatening diseases, and pet humanization trend is increasing rapidly in Asian countries.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Small Animal Respiratory Diseases Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Small Animal Respiratory Diseases Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Small Animal Respiratory Diseases Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Small Animal Respiratory Diseases Treatment market?
• Which is the largest regional market for Small Animal Respiratory Diseases Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Small Animal Respiratory Diseases Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Small Animal Respiratory Diseases Treatment market worldwide?